Dr. Hana El Sahly on Remdesivir and How Little We Still Know About COVID-19
In the coming days, Dr. Hana El Sahly of Houston’s Baylor College of Medicine will begin registering hospitalized participants at Baylor St. Luke’s Medical Center and Ben Taub Hospital for the second phase of the National Institutes of Health’s Adaptive COVID-19 Treatment Trial, or ACTT. She’s Baylor’s lead investigator for participation in the program, which in its first phase analyzed a randomized, controlled trial designed to evaluate the safety and efficacy of the investigational antiviral remdesivir. Preliminary findings suggested that patients treated with remdesivir recovered faster than patients who received a placebo, which led to the May 1 announcement that remdesivir would be the first medication to receive FDA authorization for emergency use for COVID-19. Subscribe Apple — Google Play — Stitcher — Spotify “We found that for…View Original Post
The post Dr. Hana El Sahly on Remdesivir and How Little We Still Know About COVID-19 appeared first on Texas Monthly.
Source: Texas Monthly